Oncorus Inc. (ONCR): Price and Financial Metrics
GET POWR RATINGS... FREE!
ONCR Stock Price Chart Interactive Chart >
ONCR Price/Volume Stats
| Current price | $1.29 | 52-week high | $17.79 |
| Prev. close | $1.20 | 52-week low | $1.03 |
| Day low | $1.20 | Volume | 52,200 |
| Day high | $1.30 | Avg. volume | 127,014 |
| 50-day MA | $1.49 | Dividend yield | N/A |
| 200-day MA | $5.79 | Market Cap | 33.39M |
Oncorus Inc. (ONCR) Company Bio
Oncorus, Inc. engages in the research and development of viral immunotherapies platform. It develops immunotherapy platform to treat cancer such as oncolytic Herpes Simplex Virus Platform and Synthetic Virus Platform. The company was founded by Mitchell H. Finer, Joseph C. Glorioso III, Kenneth P. Greenberg, Cyrus D. Mozayeni, and Paola Grandi on April 1, 2015 and is headquartered in Cambridge, MA.
Latest ONCR News From Around the Web
Below are the latest news stories about Oncorus Inc that investors may wish to consider to help them evaluate ONCR as an investment opportunity.
Oncorus to Present at the H.C. Wainwright BioConnect Virtual ConferenceCAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Oncorus, Inc. (NASDAQ: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in a fireside chat at the H.C. Wainwright BioConnect Conference. The fireside chat will be available for on-demand viewing beginning Monday, January 10, 2022 at 7:00am ET under the Investors & Media |
Head to Head Contrast: Kronos Bio (NASDAQ:KRON) versus Oncorus (NASDAQ:ONCR)Oncorus (NASDAQ:ONCR) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations. Insider and Institutional Ownership 79.6% of Oncorus shares are held by institutional investors. Comparatively, 68.3% of [] |
Oncorus, Inc. (NASDAQ:ONCR) Shares Purchased by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. increased its holdings in shares of Oncorus, Inc. (NASDAQ:ONCR) by 43.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 83,493 shares of the companys stock after acquiring an additional 25,477 shares during the period. Charles Schwab Investment Management [] The post Oncorus, Inc. (NASDAQ:ONCR) Shares Purchased by Charles Schwab Investment Management Inc. appeared first on ETF Daily News . |
One Oncorus, Inc. (NASDAQ:ONCR) insider upped their stake in the previous yearInsiders were net buyers of Oncorus, Inc.'s ( NASDAQ:ONCR ) stock during the past year. That is, insiders bought more... |
Oncorus to Present at Upcoming Investor ConferencesCAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, today announced that President and Chief Executive Officer, Theodore (Ted) Ashburn, M.D., Ph.D., will participate in two upcoming virtual investor conferences: 33rd Annual Piper Sandler Virtual Healthcare Conference: A corporate presentation will be available on-demand starting Monday, November 22nd at 10:00 a.m |
ONCR Price Returns
| 1-mo | N/A |
| 3-mo | -50.76% |
| 6-mo | -78.14% |
| 1-year | -91.37% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -75.52% |
| 2021 | -83.70% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...